205.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Enterprise value to EBIT forward of Axsome Therapeutics, Inc. – MUN:19X - TradingView
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits
Zacks Research Upgrades Axsome Therapeutics (NASDAQ:AXSM) to "Hold" - MarketBeat
Lisanti Capital Growth LLC Acquires Shares of 20,825 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Eagle Health Investments LP Invests $15.92 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Enterprise value to EBITDA forward of Axsome Therapeutics, Inc. – SWB:19X - TradingView
Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years - Sahm
Pallas Capital Advisors LLC Acquires Shares of 40,511 Axsome Therapeutics, Inc. $AXSM - MarketBeat
TimesSquare Capital Management LLC Takes Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 - Stocktwits
OneDigital Investment Advisors LLC Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Significant 33.58% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
GSA Capital Partners LLP Makes New $2.31 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. (AXSM) Latest Stock News & Headlines - Yahoo Finance
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $316 - Moomoo
Handelsbanken Fonder AB Has $10.38 Million Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today - Sahm
AXSM|Axsome Therapeutics Inc|Price:213.630|Chg%:-1.030 - TradingKey
Axsome Therapeutics (NASDAQ:AXSM) Faces A Crucial Test - Kalkine Media
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - simplywall.st
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
AXSOME THERAPEUTICS, INC. : MIZUHO RAISES TARGET PRICE TO $316 FROM $306 - webull.com
UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating - Moomoo
Mizuho raises Axsome Therapeutics stock price target on Auvelity By Investing.com - Investing.com South Africa
Mizuho raises Axsome Therapeutics stock price target on Auvelity - Investing.com
Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating - marketscreener.com
Quantinno Capital Management LP Acquires 5,019 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results - webull.com
AXSOME THERAPEUTICS, INC. : MORGAN STANLEY RAISES TARGET PRICE TO $251 FROM $242 - webull.com
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues - Yahoo Finance
Axsome Therapeutics (AXSM) Shares Just Climbed, So What Is Driving Attention Now? - Yahoo Finance
RBC cuts Axsome Therapeutics stock price target on model updates By Investing.com - Investing.com Australia
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition (AXSM) - Seeking Alpha
Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says - marketscreener.com
Axsome Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo
Wells Fargo raises Axsome Therapeutics price target to $256 By Investing.com - Investing.com Australia
RBC cuts Axsome Therapeutics stock price target on model updates - Investing.com
Needham raises Axsome Therapeutics stock price target on drug growth By Investing.com - Investing.com South Africa
AXSM Maintained by Wells Fargo -- Price Target Raised to $256 - GuruFocus
Guggenheim raises Axsome Therapeutics stock price target on sales beat By Investing.com - Investing.com Nigeria
Needham raises Axsome Therapeutics stock price target on drug growth - Investing.com
Morgan Stanley Adjusts Axsome Therapeutics PT to $251 From $242, Keeps Equalweight Rating - marketscreener.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $268.00 - MarketBeat
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):